Michael Wang, MD, discusses the use of acalabrutinib in the phase 2 ACE-LY-004 trial in mantle cell lymphoma.
Michael Wang, MD, professor, Department of Lymphoma/Myeloma, founding and current director, Mantle Cell Lymphoma Program of Excellence, professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of acalabrutinib (Calquence) in the phase 2 ACE-LY-004 trial (NCT02213926) in mantle cell lymphoma (MCL).
During the 2021 Pan Pacific Lymphoma Conference, long-term data from the ACE-LY-004 trial were presented, evaluating single-agent acalabrutinib in patients with relapsed/refractory MCL, Wang explains. Initial results of the study were published in The Lancet in 2018, following the 2017 FDA approval of the BTK inhibitor in this patient population.
At a median follow-up of 38.1 months, the final data from the trial demonstrated a high response rate of 89% and a complete response rate of 48% with acalabrutinib in patients with relapsed/refractory MCL, Wang continues. Notably, the median duration of response was 28.6 months, and the median progression-free survival was 22 months, Wang concludes.